Outcome
    Moderate Evidence
    Effectiveness 3/5

    Vitamin D for Flu Prevention

    Vitamin D supplementation reduced acute respiratory infections in an individual-participant meta-analysis of 25 RCTs, with the strongest protection in deficient people taking daily doses.

    Overview

    Vitamin D offers a small but real reduction in respiratory infection risk, and the size of that effect depends almost entirely on where you start. The individual participant data meta-analysis of 25 randomised trials — the highest-quality evidence available on this question — found protection against acute respiratory infection overall, with substantially greater benefit in people who were deficient at baseline and in those given regular daily or weekly doses rather than large intermittent boluses. So the honest framing is corrective rather than pharmacological. If your 25-hydroxyvitamin D is below about 25 nmol/L, fixing that meaningfully lowers your odds of a respiratory infection this winter. If you are already replete, the expected benefit shrinks toward nothing. Vitamin D is a complement to influenza vaccination, not an alternative to it.

    Verdict

    Likely effective

    An individual participant data meta-analysis of randomised trials shows daily or weekly vitamin D reduces acute respiratory infection risk, with the largest effect in people who were deficient at baseline. Influenza-specific trials are mixed but lean positive.

    How It Works

    The link between vitamin D and respiratory defence runs through innate immunity. Airway epithelial cells and macrophages express both the vitamin D receptor and the enzyme that converts circulating 25-hydroxyvitamin D into its active form locally, so the tissue makes its own active hormone when substrate is available. Activation induces cathelicidin and beta-defensin, antimicrobial peptides that disrupt viral envelopes and bacterial membranes at the mucosal surface. Vitamin D also modulates the adaptive response, dampening pro-inflammatory Th1 and Th17 cytokine production while supporting regulatory T cells — which may matter more for the severity of an infection than for catching one. The seasonality argument follows naturally: 25-hydroxyvitamin D falls through winter at higher latitudes at exactly the point influenza circulation peaks, though seasonality alone cannot prove causation.

    Pathways involved

    Cathelicidin and defensin induction
    Local 1-alpha-hydroxylase activity in airway cells
    Mucosal barrier integrity
    Th1 and Th17 cytokine modulation
    Regulatory T cell support

    Dosing & Protocol

    Dosing frequency turned out to be the decisive variable. The individual participant data meta-analysis found protection with daily or weekly regimens and none with large intermittent bolus doses of 30,000 IU or more, which appear to disturb vitamin D metabolism and raise catabolic enzyme activity. Practically, that means 800 to 2,000 IU per day rather than a single monthly megadose. The schoolchildren influenza A trial used 1,200 IU daily through winter; the inflammatory bowel disease trial used higher doses in a population with absorption problems. A reasonable general target is 1,000 to 2,000 IU daily from autumn to spring, adjusted by measured 25-hydroxyvitamin D where available, aiming for a level above 50 nmol/L. Take it with the largest meal of the day — vitamin D is fat soluble and absorption improves substantially with dietary fat.
    ScenarioDoseFrequencyNotes
    General winter prevention1,000-2,000 IU/dayDaily, with a fatty mealAutumn through spring at higher latitudes
    Schoolchildren influenza A trial1,200 IU/dayDaily through winterReduced influenza A incidence versus placebo
    Documented deficiency (<25 nmol/L)Loading then 800-2,000 IU/dayDaily, per clinicianLargest expected benefit
    Weekly alternative7,000-14,000 IUWeeklyEquivalent to daily in the meta-analysis
    Not effective30,000+ IU bolusesMonthly or less oftenNo protective effect in pooled analysis
    Upper limit4,000 IU/dayDailyAbove this only with monitoring
    1. 1

      Get the influenza vaccine· Autumn

      Vaccination remains the intervention with by far the strongest evidence for preventing influenza. Vitamin D sits alongside it, not instead of it.

    2. 2

      Test if you can· Before starting

      A 25-hydroxyvitamin D level tells you whether you are in the group that benefits. Below 25 nmol/L is where the effect concentrates.

    3. 3

      Take 1,000-2,000 IU daily· Autumn to spring

      Daily or weekly dosing only. With the largest meal of the day for absorption.

    4. 4

      Avoid the megadose shortcut· Ongoing

      Large intermittent boluses showed no protective effect in the pooled analysis and may be counterproductive.

    5. 5

      Recheck if you started deficient· Month 3

      Repeat the level after about three months to confirm you have moved above 50 nmol/L, then settle on a maintenance dose.

    Evidence

    The 2019 individual participant data meta-analysis in Health Technology Assessment pooled raw data from 25 randomised trials and around 11,000 participants. It found an overall reduction in acute respiratory infection risk, with the effect concentrated in participants with baseline 25-hydroxyvitamin D below 25 nmol/L and in those receiving daily or weekly rather than bolus dosing. Because it uses participant-level rather than study-level data, it is the most reliable answer available. The influenza-specific trials are smaller and less uniform. The 2010 American Journal of Clinical Nutrition trial in Japanese schoolchildren found 1,200 IU daily reduced laboratory-confirmed influenza A. A 2019 randomised trial in inflammatory bowel disease patients and a 2022 trial in children examining seasonal influenza and enterovirus produced more mixed results, with benefit that did not always reach significance for influenza specifically. Taken together: a modest, real effect on respiratory infection broadly, less certain when narrowed to influenza alone.
    Best available evidence
    Individual participant data meta-analysis of 25 randomised trials, plus three randomised influenza-specific trials
    Typical effect
    Modest reduction in acute respiratory infection; larger in baseline deficiency
    Who benefits most
    People with 25-hydroxyvitamin D below 25 nmol/L
    Effective regimen
    Daily or weekly dosing; bolus dosing showed no benefit
    Studied dose
    800-2,000 IU/day, 1,200 IU/day in the schoolchildren trial
    Certainty of evidence
    Moderate for respiratory infection overall; lower for influenza specifically

    The individual participant data meta-analysis of vitamin D for acute respiratory infection prevention, plus randomised trials in schoolchildren, children with seasonal influenza and enterovirus exposure, and patients with inflammatory bowel disease.

    Vitamin D supplementation to prevent acute respiratory infections: individual participant data meta-analysis

    Score: 8/10
    2019
    meta_analysis

    Vitamin D supplementation reduced acute respiratory infection risk, with greatest benefit at baseline 25(OH)D below 25 nmol/L.

    View source

    Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren

    Score: 7/10
    2010
    rct
    n=334

    Influenza A occurred in 10.8% of children in the vitamin D3 group compared with 18.6% in the placebo group.

    View source

    A randomized trial of vitamin D supplementation to prevent seasonal influenza and enterovirus infection in children

    Score: 7/10
    2022
    rct
    n=248

    Vitamin D supplementation did not significantly reduce the incidence of influenza and enterovirus infection in Taiwanese children.

    View source

    Randomized Trial of Vitamin D Supplementation to Prevent Seasonal Influenza and Upper Respiratory Infection in Patients With Inflammatory Bowel Disease

    Score: 6/10
    2019
    rct
    n=223

    Vitamin D 500 IU/day did not reduce the incidence of influenza in patients with inflammatory bowel disease.

    View source

    Safety

    At 1,000 to 2,000 IU daily vitamin D is very safe, and adverse event rates in the pooled trials did not differ from placebo. The tolerable upper intake level for adults is 4,000 IU per day; toxicity is essentially confined to sustained intakes far above that, usually 10,000 IU or more daily over months, or to accidental overdosing from mislabelled products. When toxicity does occur it presents as hypercalcaemia: nausea, vomiting, thirst, frequent urination, confusion, and with prolonged exposure kidney stones and renal impairment. Certain conditions raise the risk at ordinary doses — sarcoidosis, tuberculosis and other granulomatous diseases convert vitamin D to its active form without normal feedback control, as do some lymphomas. Primary hyperparathyroidism and significant chronic kidney disease also need supervised dosing rather than self-treatment.

    Vaccination first

    Vitamin D is a modest adjunct. Influenza vaccination remains the intervention with the strongest evidence for preventing flu and its complications, particularly in older adults and those with chronic conditions.

    Interactions & Conflicts

    Interacts withSeverityMechanismAction
    Thiazide diuretics
    moderate
    		Reduced urinary calcium excretion plus vitamin D raises hypercalcaemia riskMonitor calcium if using higher doses
    Sarcoidosis and granulomatous disease
    high
    		Unregulated conversion to active vitamin D causes hypercalcaemiaOnly under specialist supervision
    Digoxin
    moderate
    		Hypercalcaemia increases digoxin toxicity riskMonitor calcium and digoxin levels
    Corticosteroids
    low
    		Reduce vitamin D metabolism and calcium absorptionRequirements may be higher
    Orlistat, cholestyramine and bile acid sequestrants
    moderate
    		Reduced absorption of fat-soluble vitaminsSeparate doses by several hours
    Anticonvulsants (phenytoin, phenobarbital, carbamazepine)
    moderate
    		Accelerated catabolism of vitamin DHigher doses often needed; monitor levels
    Chronic kidney disease
    moderate
    		Impaired activation and altered calcium-phosphate handlingDosing directed by nephrology

    References

    1. Martineau AR et al. Vitamin D supplementation to prevent acute respiratory infections: individual participant data meta-analysis. Health Technol Assess. 2019
    2. Urashima M et al. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Am J Clin Nutr. 2010
    3. Arihiro S et al. Randomized trial of vitamin D supplementation to prevent seasonal influenza and upper respiratory infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2019

    Frequently Asked Questions

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.